Intraflagellar transport protein 57 homolog (IFT57)

Intraflagellar transport protein 57 homolog (IFT57) is a critical adaptor and structural subunit of the IFT-B complex responsible for anterograde protein transport along the microtubules in cilia. It stabilizes IFT particle complexes via interaction with other IFT proteins (IFT38, IFT52, IFT88), essential for ciliary assembly, maintenance, and functional signaling, notably of the Hedgehog pathway. IFT57 also has pro-apoptotic roles via the HIP1/caspase-8 axis, may bind DNA and regulate apoptotic gene promoters, and is involved in several human genetic diseases—especially ciliopathies such as Bardet-Biedl syndrome and oral-facial-digital syndrome type 18. Genetic mutations in IFT57 result in congenital developmental defects, including retinal degeneration and kidney disease, due to impaired ciliary function[1][2][3][4][5]. If further structural data or drug-interaction information emerges, it may inform more precise roles in therapy or disease monitoring, but currently no drugs are reported to target IFT57 directly.

Other names

HIPPI (HIP1-interacting protein)DERP8 (Dermal papilla-derived protein 8)ESRRBL1 (Estrogen-related receptor beta-like protein 1)MHS4R2OFD18IFT57Huntingtin interacting protein-1 interacting proteinIntraflagellar transport protein 57 homologFLJ10147

No established drug-based mechanism of action. In experimental systems, gene editing or overexpression can rescue cilia defects. Theoretically, drugs could target apoptotic or ciliary pathways involving HIP1 or caspase-8 activation, but no specific pharmacology is reported.